S. Saito

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
S Saito, S. Saito, Satoru Saito
Publication record
272 papers · 8,082 citations · H-index 45

PAPERS

Identification of differentially methylated regions associated with both liver fibrosis and hepatocellular carcinoma
20245 citationsauthor #8
Prior appendectomy and cerebral infarction as potential risk factors for recurrent ischemic colitis: A retrospective observational study
20230 citationsauthor #9
M‐PAST score is better than MAST score for the diagnosis of active fibrotic nonalcoholic steatohepatitis
20236 citationsauthor #23
Frontiers of Collaboration between Primary Care and Specialists in the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review
20238 citationsauthor #7
Prediction of outcomes in patients with metabolic dysfunction-associated steatotic liver disease based on initial measurements and subsequent changes in magnetic resonance elastography
202315 citationsauthor #9
Prediction of outcomes in patients with non-alcoholic fatty liver disease by initial measurements and subsequent changes in magnetic resonance elastography
20230 citationsauthor #5
Involvement of Periodontal Disease in the Pathogenesis and Exacerbation of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis: A Review
20239 citationsauthor #7
Combined, elobixibat, and colestyramine reduced cholesterol toxicity in a mouse model of metabolic dysfunction-associated steatotic liver disease
20231 citationsauthor #14
Impact of Sarcopenia on Non-Alcoholic Fatty Liver Disease
202345 citationsauthor #4
Meta‐analysis of the diagnostic accuracy of serum type IV collagen 7S concentration for the staging of liver fibrosis in nonalcoholic fatty liver disease
20232 citationsauthor #12
Nonalcoholic Fatty Liver Disease as a Systemic Disease and the Need for Multidisciplinary Care
202310 citationsauthor #5
Effectiveness of Naldemedine Compared with Magnesium Oxide in Preventing Opioid-Induced Constipation: A Randomized Controlled Trial
202223 citationsauthor #22
Prior appendectomy and cerebral infarction as potential risk factors for recurrent ischemic colitis: a case control study
20220 citationsauthor #10
Real‐world assessment of SmartExam, a novel FibroScan computational method: A retrospective single‐center cohort study
202211 citationsauthor #10
Two differentially methylated region networks in nonalcoholic fatty liver disease, viral hepatitis, and hepatocellular carcinoma
20224 citationsauthor #7
Association of Serum and Fecal Bile Acid Patterns With Liver Fibrosis in Biopsy-Proven Nonalcoholic Fatty Liver Disease: An Observational Study
202228 citationsauthor #32
Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future
202229 citationsauthor #8
Comparison of long‐term prognosis between non‐obese and obese patients with non‐alcoholic fatty liver disease
20225 citationsauthor #16
Efficacy and safety of guanabenz acetate treatment for non-alcoholic fatty liver disease: a study protocol for a randomised investigator-initiated phase IIa study
20222 citationsauthor #15
Combination of tofogliflozin and pioglitazone for NAFLD: Extension to the ToPiND randomized controlled trial
202231 citationsauthor #10
New scoring system using MRI with AST for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis
20220 citationsauthor #20
A 3-step approach to predict advanced fibrosis in nonalcoholic fatty liver disease: impact on diagnosis, patient burden, and medical costs
20225 citationsauthor #10
Diagnostic comparison of vibration-controlled transient elastography and MRI techniques in overweight and obese patients with NAFLD
202226 citationsauthor #12
A pediatric case of Stevens‐Johnson syndrome with acute liver failure, resulting in liver transplantation
20217 citationsauthor #8
Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan
202177 citationsauthor #12
Endotoxins and Non-Alcoholic Fatty Liver Disease
202174 citationsauthor #21
Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial
202188 citationsauthor #14
Quantitative multiparametric magnetic resonance imaging can aid non-alcoholic steatohepatitis diagnosis in a Japanese cohort
202134 citationsauthor #13
Vitamin B6 efficacy in the treatment of nonalcoholic fatty liver disease: an open-label, single-arm, single-center trial.
202117 citationsauthor #9
The Role of Leaky Gut in Nonalcoholic Fatty Liver Disease: A Novel Therapeutic Target
202158 citationsauthor #19
MRI‐Based Quantitative R2* Mapping at 3 Tesla Reflects Hepatic Iron Overload and Pathogenesis in Nonalcoholic Fatty Liver Disease Patients
202119 citationsauthor #13
Pan-peroxisome proliferator-activated receptor agonist lanifibranor as a dominant candidate pharmacological therapy for nonalcoholic fatty liver disease.
202112 citationsauthor #5
Lymphoepithelioma-like cholangiocarcinoma with Epstein–Barr virus infection treated by radiofrequency ablation
202112 citationsauthor #2
Protective effect of SGL5213, a potent intestinal sodium-glucose cotransporter 1 inhibitor, in nonalcoholic fatty liver disease in mice.
202110 citationsauthor #11
III. Non-alcoholic Fatty Liver Disease (NAFLD) /Non-alcoholic Steatohepatitis (NASH)
20210 citationsauthor #2
Gastroesophageal varices evaluation using spleen‐dedicated stiffness measurement by vibration‐controlled transient elastography
202129 citationsauthor #13
What considerations are there for the pharmacotherapeutic management of nonalcoholic steatohepatitis?
20215 citationsauthor #3
Influence of liver stiffness heterogeneity on staging fibrosis in patients with nonalcoholic fatty liver disease
202123 citationsauthor #15
Gut microbiota composition associated with hepatic fibrosis in non‐obese patients with non‐alcoholic fatty liver disease
202133 citationsauthor #27
Magnetic resonance imaging for the assessment of pathological hepatic findings in nonalcoholic fatty liver disease
20209 citationsauthor #4
A case of hepatitis B virus reactivation with hemochromatosis after allogeneic bone marrow transplantation for acute myeloid leukemia
20200 citationsauthor #12
Efficacy and safety of combination therapy with elobixibat and colestyramine for non-alcoholic steatohepatitis model mice
20200 citationsauthor #9
A review of conventional and newer generation microwave ablation systems for hepatocellular carcinoma
202032 citationsauthor #4
Lubiprostone in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled, phase 2a trial.
202038 citationsauthor #20
Metabolomic-/Lipidomic-based Analysis of Plasma to Diagnose Hepatocellular Ballooning in Patients with Nonalcoholic Fatty Liver Disease: A Multicenter Study.
202015 citationsauthor #22
Efficacy of Lubiprostone in Patients with Non-Alcoholic Fatty Liver Disease: A Randomized, Double-Blind, Placebo-Controlled, Phase 2A Trial
20200 citationsauthor #20
Complications of Non-Alcoholic Fatty Liver Disease in Extrahepatic Organs
202029 citationsauthor #17
Coronary Artery Disease is More Severe in Patients with Non-Alcoholic Steatohepatitis than Fatty Liver
202024 citationsauthor #11
Rationale and design of a randomised, double-blind, placebo-controlled, parallel-group, investigator-initiated phase 2a study to investigate the efficacy and safety of elobixibat in combination with cholestyramine for non-alcoholic fatty liver disease
20208 citationsauthor #14
Direct comparison of US and MR elastography for staging liver fibrosis in patients with nonalcoholic fatty liver disease.
2020105 citationsauthor #15
Effect of tofogliflozin and pioglitazone on hepatic steatosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A randomized, open-label pilot study (ToPiND study)
201913 citationsauthor #14
Comparing the effectiveness of magnesium oxide and naldemedine in preventing opioid-induced constipation: a proof of concept, single institutional, two arm, open-label, phase II, randomized controlled trial: the MAGNET study
20196 citationsauthor #16
GS-01-Efficacy, safety, and tolerability of lubiprostone for the treatment of non-alcoholic fatty liver disease: The LUBIPRONE, doubleblind, randomized, placebo-controlled, phase II study
20190 citationsauthor #17
SAT-307-A direct comparative study among magnetic resonance elastography, vibration controlled transient elastography and shear wave elastography in patients with non-alcoholic fatty liver disease
20190 citationsauthor #7
Assessment of 10‐year changes in liver stiffness using vibration‐controlled transient elastography in non‐alcoholic fatty liver disease
201919 citationsauthor #13
Microbiota in Non-alcoholic Liver Disease
20190 citationsauthor #7
SAT-306-Autotaxin is a valuable biomarker for predicting liver fibrosis in patients with non-alcoholic fatty liver disease
20190 citationsauthor #7
Distribution of liver stiffness in non‐alcoholic fatty liver disease with higher fibrosis‐4 index than low cut‐off index
20196 citationsauthor #12
FRI-312-Increased levels of bile acid in feces plays an important role in pathophysiology of non-alcoholic steatohepatitis
20191 citationsauthor #14
Relationship between Stool Form and Quality of Life in Patients with Chronic Constipation: An Internet Questionnaire Survey
201931 citationsauthor #12
Autotaxin is a valuable biomarker for the prediction of liver fibrosis in patients with non‐alcoholic fatty liver disease
201928 citationsauthor #9
Faecalibacterium improves pathogenesis of nonalcoholic steatohepatitis via controlling Treg induced gut-permeability
20182 citationsauthor #9
Wisteria floribunda agglutinin‐positive Mac‐2‐binding protein and type 4 collagen 7S: useful markers for the diagnosis of significant fibrosis in patients with non‐alcoholic fatty liver disease
201841 citationsauthor #11
Efficacy, safety, and tolerability of lubiprostone for the treatment of non-alcoholic fatty liver disease in adult patients with constipation: The LUBIPRONE, double-blind, randomised, placebo-controlled study design.
20185 citationsauthor #17
Magnetic resonance elastography increases usefulness and safety of non‐invasive screening for esophageal varices
201823 citationsauthor #11
Palmitate-induced lipotoxicity is crucial for the pathogenesis of nonalcoholic fatty liver disease in cooperation with gut-derived endotoxin
20189 citationsauthor #9
[Gut microbiota and nonalcoholic steatohepatitis].
20182 citationsauthor #7
Present and emerging pharmacotherapies for non-alcoholic steatohepatitis in adults
201816 citationsauthor #7
A new system for microwave ablation is useful for the treatment of unresectable liver tumors via forming the large and spherical ablation zone
20185 citationsauthor #15
Identification of the genomic region under epigenetic regulation during non‐alcoholic fatty liver disease progression
201839 citationsauthor #10
Palmitate-induced lipotoxicity is crucial for the pathogenesis of nonalcoholic fatty liver disease in cooperation with gut-derived endotoxin
2018107 citationsauthor #9
Analyze of ballooning biomarker in patients with non-alcoholic steatohepatitis: A multicenter study
20180 citationsauthor #6
Identification of differentially methylated region (DMR) networks associated with progression of nonalcoholic fatty liver disease
201836 citationsauthor #10
New microwave ablation system for unresectable liver tumors that forms large, spherical ablation zones
201815 citationsauthor #14
A case of Castleman disease complicating chronic hepatitis C
20170 citationsauthor #13
Efficacy of glutathione for the treatment of nonalcoholic fatty liver disease: an open-label, single-arm, multicenter, pilot study
201798 citationsauthor #16
Clinical strategy of diagnosing and following patients with nonalcoholic fatty liver disease based on invasive and noninvasive methods
201760 citationsauthor #9
Characteristics of Fecal Microbiota in Japanese Patients with Nonalcoholic Fatty Liver Disease: A Connection among Gut-Permeability, Endotoxin and NAFLD
20176 citationsauthor #12
Identification of core gene networks and hub genes associated with progression of non‐alcoholic fatty liver disease by RNA sequencing
201725 citationsauthor #14
Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis
2017109 citationsauthor #9
The Characteristics of Non-Obese Non-Alcoholic Fatty Liver Disease: Effect of Genetic and Environmental Factors
20160 citationsauthor #6
The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice
2016157 citationsauthor #11
Saturated Fatty Acid, Palmitate, Induced Liver Inflammation and Fibrosis in Vivo
20160 citationsauthor #9
Characteristics of non‐obese non‐alcoholic fatty liver disease: Effect of genetic and environmental factors
201664 citationsauthor #12
A case of liver infarction complicating the HELLP syndrome
20160 citationsauthor #9
Magnetic Resonance Imaging More Accurately Classifies Steatosis and Liver Fibrosis in Non-Alcoholic Fatty Liver Disease than Transient Elastography
20162 citationsauthor #9
Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography.
2016714 citationsauthor #17
Resveratrol ameliorates fibrosis and inflammation in a mouse model of nonalcoholic steatohepatitis
201683 citationsauthor #12
Early effects of oral administration of esomeprazole and omeprazole on the intragastric pH.
20152 citationsauthor #15
Non‐alcoholic fatty liver disease comorbid with major depressive disorder: The pathological features and poor therapeutic efficacy
201595 citationsauthor #11
Non‐alcoholic fatty liver disease comorbid with major depressive disorder: The pathological features and poor therapeutic efficacy
201595 citationsauthor #4
Deficiency of eNOS exacerbates early-stage NAFLD pathogenesis by changing the fat distribution
201542 citationsauthor #10
Targeted-bisulfite sequence analysis of the methylation of CpG islands in genes encoding PNPLA3, SAMM50, and PARVB of patients with non-alcoholic fatty liver disease.
201574 citationsauthor #6
Deficiency of iNOS-derived NO accelerates lipid accumulation-independent liver fibrosis in non-alcoholic steatohepatitis mouse model
201534 citationsauthor #10
Screening of nonalcoholic fatty liver disease in patients with coronary heart disease by transient elastography: proceed with caution
20140 citationsauthor #3
Sa1707 Analysis of Lipotoxicity in Liver Induced by Palmitate In Vivo
20140 citationsauthor #9
Oral choline tolerance test as a novel noninvasive method for predicting nonalcoholic steatohepatitis
201410 citationsauthor #15
P270 MICRO RNA-27B CAUSES NONALCOHOLIC STEATOHEPATITIS SIMILAR TO HUMAN PATHOPHYSIOLOGY IN MURINE HIGH-FAT DIET MODEL
20141 citationsauthor #10
LDL-Migration Index (LDL-MI), an Indicator of Small Dense Low-Density Lipoprotein (sdLDL), Is Higher in Non-Alcoholic Steatohepatitis than in Non-Alcoholic Fatty Liver: A Multicenter Cross-Sectional Study
201438 citationsauthor #13
PPARs and Liver Disease
20130 citationsauthor #8

TIMELINE

2001 28 citations

2005 44 citations

2006 75 citations

2007 859 citations

2008 1,231 citations

2009 984 citations

2010 876 citations

2011 253 citations

2012 423 citations

2013 183 citations

2014 49 citations

2015 247 citations

2016 1,020 citations

2017 298 citations

2018 300 citations

2019 104 citations

2020 260 citations

2021 498 citations

2022 164 citations

2023 96 citations

2024 5 citations

S. Saito

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT